Abstract
Tyrosine kinase inhibitors (TKIs), the standard treatment for chronic phase chronic myeloid leukemia (CP-CML), are generally avoided during pregnancy because of teratogenic risk. Peginterferon alfa-2a may be used when treatment is required, although pregnancy data are limited. This case discusses a 31-year-old woman at 8 weeks’ gestation who was diagnosed with CP-CML after presenting with leukocytosis and thrombocytosis. She began peginterferon alfa-2a 90 µg weekly and maintained an adequate hematologic response with mild transaminitis, ultimately delivering a healthy infant. She transitioned to dasatinib postpartum. This case supports peginterferon alfa-2a as a potential option for hematologic control of CP-CML during pregnancy when TKIs are avoided.
References
Abruzzese, E., & Chelysheva, E. (2026). How I manage chronic myeloid leukemia during pregnancy. Blood, 147(4), 347–356. https://doi.org/10.1182/blood.2024026513
Assi, R., Kantarjian, H., Keating, M., Pemmaraju, N., Verstovsek, S., Garcia-Manero, G., Ravandi, F., Borthakur, G., Dahl, J., Jabbour, E., & Cortes, J. E. (2021). Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: A single-center experience. Leukemia & Lymphoma, 62(4), 909–917. https://doi.org/10.1080/10428194.2020.1849672
Chelysheva, E., Abruzzese, E., Rea, D., Kim, D.-W., Kazakbaeva, K., Saliev, S., Kotlyarchuk, K., Polushkina, E., Shmakov, R., Chabaeva, J., Kulikov, S. M., & Turkina, A. G. (2018). Chronic myeloid leukemia diagnosed during pregnancy: Therapy, outcomes and follow-up. Blood, 132(Supplement 1), 4255. https://doi.org/10.1182/blood-2018-99-115983
Chelysheva, E., Apperley, J., Turkina, A., Yassin, M. A., Rea, D., Nicolini, F. E., Barraco, D., Kazakbaeva, K., Saliev, S., Shacham Abulafia, A., Al-Kindi, S., Byrne, J., Robertson, H. F., Cerrano, M., Shmakov, R., Polushkina, E., de Fabritiis, P., Trawinska, M. M., & Abruzzese, E. (2024). Chronic myeloid leukemia diagnosed in pregnancy: Management and outcome of 87 patients reported to the European LeukemiaNet international registry. Leukemia, 38(4), 788–795. https://doi.org/10.1038/s41375-024-02183-0
Dulucq, S., & Mahon, F.-X. (2016). Deep molecular responses for treatment-free remission in chronic myeloid leukemia. Cancer Medicine, 5(9), 2398–2411. https://doi.org/10.1002/cam4.801
Haddad, F. G., Croden, J., Sasaki, K., Issa, G. C., Pemmaraju, N., Kantarjian, H., & Jabbour, E. (2026). Management of chronic myeloid leukemia during pregnancy: Review of evidence and treatment algorithm. Clinical Lymphoma, Myeloma & Leukemia, 26(1), 19–25. https://doi.org/10.1016/j.clml.2025.07.017
Jabbour, E., & Kantarjian, H. (2025). Chronic myeloid leukemia: A review. JAMA, 333(18), 1618–1629. https://doi.org/10.1001/jama.2025.0220
Mahon, F.-X., Pfirrmann, M., Dulucq, S., Hochhaus, A., Panayiotidis, P., Almeida, A., Mayer, J., Hjorth-Hansen, H., Janssen, J. J. W. M., Mustjoki, S., Martinez-Lopez, J., Vestergaard, H., Ehrencrona, H., Machová Poláková, K., Olsson-Strömberg, U., Ossenkoppele, G., Berger, M. G., Etienne, G., Dengler, J., … Saussele, S. (2024). European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in chronic myeloid leukemia: Final analysis and novel prognostic factors for treatment-free remission. Journal of Clinical Oncology, 42(16), 1875–1880. https://doi.org/10.1200/JCO.23.01647
Pua, N., Thiruselvan, H., Douglas, A., Anazodo, A., Kidson-Gerber, G., & Hamad, N. (2025). Management of chronic myeloid leukaemia (CML) during pregnancy: A systematic review of maternal and foetal outcomes. Blood, 146(Supplement 1), 2845–2846. https://doi.org/10.1182/blood-2025-2845
Robertson, H. F., & Apperley, J. F. (2022). Treatment of CML in pregnancy. Hematology, 2022(1), 123–128. https://doi.org/10.1182/hematology.2022000330
Robertson, H. F., Milojkovic, D., Butt, N., Byrne, J., Claudiani, S., Copland, M., Gallipoli, P., Innes, A. J., Knight, K., Mahdi, A. J., Parker, J., Virchis, A., & Apperley, J. F. (2024). Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy. British Journal of Haematology, 205(3), 947–955. https://doi.org/10.1111/bjh.19491
